ArticleBlood advances2020

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

Jayakumar Vadakekolathu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.